(Q38074017)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ricky W Johnstone

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

A K Hsu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

14 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

4191-4202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2012.599

22 February 2020

exact match

0 references

cites work

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide metabolism and hydrolysis: mechanisms and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Antimyeloma efficacy of thalidomide in the SCID-hu model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Teratogenic effects of thalidomide: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Mechanism of action in thalidomide teratogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Primary function analysis of human mental retardation related gene CRBN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Cereblon is expressed in the retina and binds to voltage-gated chloride channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Functional modulation of AMP-activated protein kinase by cereblon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide: lack of mutagenic activity across phyla and genetic endpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

SOCS regulation of the JAK/STAT signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Distinct haematological disorder with deletion of long arm of no. 5 chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

IRF4 addiction in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Oncogenically active MYD88 mutations in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Up on the tightrope: natural killer cell activation and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

DDB1-DDB2 (xeroderma pigmentosum group E) protein complex recognizes a cyclobutane pyrimidine dimer, mismatches, apurinic/apyrimidinic sites, and compound lesions in DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Pharmacokinetics of thalidomide in an elderly prostate cancer population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Structures of zinc finger domains from transcription factor Sp1. Insights into sequence-specific protein-DNA recognition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Deregulated cytokine network and defective Th1 immune response in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8 + CD57 + CD28 − compartment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Lenalidomide enhances anti-myeloma cellular immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.599

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/ONC.2012.599

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23318436%20AND%20SRC:MED&resulttype=core&format=json